Are you or a loved one living with HER2+ breast cancer?

If so, learn about HER2CLIMB, a study testing the effects of an investigational medication in combination with standard treatments in patients with locally advanced or metastatic HER2+ breast cancer. You may be able to participate in the HER2CLIMB study even if you have brain metastases.

About the HER2CLIMB Study

The HER2CLIMB study is testing the safety and efficacy of tucatinib (ONT-380), an investigational medication. Tucatinib is designed specifically to target and inhibit the growth of HER2+ cancer cells. Select patients with metastatic HER2+ breast cancer, including those who have brain metastases, may be enrolled into this clinical trial. Tucatinib is an oral medication that can be taken at home.

By participating in the HER2CLIMB study, you may benefit by:

  • Taking an active role in your own healthcare
  • Gaining access to study-related care and currently approved treatments
  • Helping others by contributing to medical research and shaping the future of medical care

 

There are also risks involved in the HER2CLIMB study, including:

  • Possible side effects from study medication
  • This investigational medication may have little, if any, benefit
  • The study will require time for traveling to the study site and for office visits

 

Eligible participants in HER2CLIMB will receive standard, approved treatments. In addition, you may also receive the investigational medication tucatinib.

Common Questions About Clinical Trials

Am I Eligible for the HER2CLIMB Study?

To be eligible for the HER2CLIMB study you must have:

  • A diagnosis of locally advanced or metastatic HER2+ breast cancer
  • Already have received the following four common therapies for the treatment of breast cancer:
    • a taxane (Taxotere® or Taxol®)
    • trastuzumab (Herceptin®)
    • pertuzumab (Perjeta®)
    • T-DM1 (Kadcyla®)

Eligible patients may or may not have brain metastases

Eligible participants in HER2CLIMB will receive standard, approved treatments. In addition, you may also receive the investigational medication tucatinib (ONT-380).

If you enroll in the HER2CLIMB study, you may receive reimbursement for approved travel expenses associated with participating in the study. Your cancer prognosis may or may not improve by taking part in the HER2CLIMB study.

How Can I Learn More About HER2CLIMB?

Start by using the map to find a study location near you. You will be asked a few questions and a study representative from the closest site will contact you to provide more information and help determine if you may be eligible.

      Share information about the HER2CLIMB study with others

      To share this study information with others via email, click here

      FacebookTwitterGoogle+